Pharmaceutical oral formulation comprising bacteria

Abstract

The present invention relates to a pharmaceutical oral formulation for use in the administration of at least two bacteria derived from fecal microbiota to mammals for the treatment and/or prevention of dysbiosis and associated pathologies. The pharmaceutical oral formulation is encapsulated mixture of at least two bacteria derived from fecal microbiota wherein the capsules are coated in a pH responsive polymer composition comprising: a. 50-70% poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1 by weight of dry polymer, b. 10-30% poly(methacrylic acid-co-ethyl acrylate) 1:1 by weight of dry polymer, c. at least one fatty acid mono-, di- or tri-glyceride ester, or mixtures thereof, d. at least one plasticizer, e. at least one non-ionic emulsifier. The pharmaceutical oral formulation is especially designed to be delivered principally in the ileum and colon and to maintain the sample bacterial viability and diversity.

Dependencies are inferred from the claim text.